Wie hoch ist der Preis für Pell Bio-Med Technology Co., Ltd. (6949)

Preis für Pell Bio-Med Technology Co., Ltd. (6949) ist $47.38

Wie hoch ist die Marktkapitalisierung für Pell Bio-Med Technology Co., Ltd. (6949)

Marktkapitalisierung für Pell Bio-Med Technology Co., Ltd. (6949) ist $3.11B

Pell Bio-Med Technology Co., Ltd. (6949) Dividendenrendite

Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio encompasses good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) utilized in regenerative medicine, and both CIK and DC-CIK therapies aimed at combating various cancers. Beyond its existing products, Pell Bio-Med is actively engaged in developing novel pharmaceuticals for diverse cancer types, pioneering cell immunotherapy strategies, and advancing stem cell regenerative therapy techniques. Its research and development efforts extend to cutting-edge areas such as chimeric antigen receptor T cell (CAR-T), CAR-NK, CAR-?dT, and genetically modified ADSC technologies. The company is also progressing product development specifically targeting indications like B-cell non-Hodgkin lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer.

Jahr	Dividendenrendite	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Dividendenrendite

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Dividendenrendite	Land
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Moderna, Inc. MRNA.US	0.00%	US
CSL Limited CSL.AX	3.12%	AU
Lonza Group AG LONN.SW	0.00%	CH

Unternehmen

Dividendenrendite

Land